Krystal Biotech Inc (KRYS) Received its Third Buy in a Row


After William Blair and Cantor Fitzgerald gave Krystal Biotech Inc (NASDAQ: KRYS) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on Krystal Biotech Inc today and set a price target of $50. The company’s shares closed yesterday at $25.07.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 15.7% and a 45.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Logicbio Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Krystal Biotech Inc with a $38.67 average price target, implying a 54.2% upside from current levels. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $34 price target.

See today’s analyst top recommended stocks >>

Based on Krystal Biotech Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $2.76 million. In comparison, last year the company had a GAAP net loss of $1.39 million.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KRYS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.